银诺医药上市首日大涨206.5%

Core Viewpoint - Silver诺医药 (02591.HK) made a strong debut on the Hong Kong Stock Exchange, with a significant increase of 206.5% on its first trading day, closing at HKD 57.25 per share, resulting in a total market capitalization of HKD 26.15 billion [1] Company Overview - Silver诺医药 was established in 2014 and focuses on the discovery, development, and commercialization of innovative therapies for diabetes and other metabolic diseases [1] - The company has developed a pipeline of candidate drugs targeting diabetes and other metabolic disorders [1] Market Response - The public offering portion of Silver诺医药 was oversubscribed by 5,341.66 times, indicating strong investor interest [1]